MedTrace Logo

Effectiveness of Rifabutin in the Treatment of Mycobacterium Avium Complex

NCT03164291 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 170

Last updated 2017-05-23

No results posted yet for this study

Summary

Treatment of adults with chronic Mycobacterium avium-intracellulare complex lung infections who have failed or are intolerant of rifampin.

Rifabutin may be a reasonable alternative agent in patients who fail rifampin or or intolerant of rifampin.

Conditions

  • Nontuberculous Mycobacterial Infections

Interventions

DRUG

Rifabutin

Rifabutin dosage dependent on clinical factors such as age, weight, and patient-specific health status

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • The University of Texas Health Science Center at Tyler

    lead OTHER

Principal Investigators

  • Richard J Wallace, Jr, M.D. · The University of Texas Health Center at Tyler

  • William B Girard, MD · University of Texas Health Science Center IRB Chair

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1984-06-30
Primary Completion
2006-09-30
Completion
2017-05-18

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03164291 on ClinicalTrials.gov